Literature DB >> 16139734

Cerebrospinal fluid and serum markers of inflammation in autism.

Andrew W Zimmerman1, Harumi Jyonouchi, Anne M Comi, Susan L Connors, Sheldon Milstien, Angeliki Varsou, Melvyn P Heyes.   

Abstract

Systemic immune abnormalities have no known relevance to brain dysfunction in autism. In order to find evidence for neuroinflammation, we compared levels of sensitive indicators of immune activation: quinolinic acid, neopterin, and biopterin, as well as multiple cytokines and cytokine receptors, in cerebrospinal fluid and serum from children with autism, to control subjects with other neurologic disorders. In cerebrospinal fluid from 12 children with autism, quinolinic acid (P = 0.037) and neopterin (P = 0.003) were decreased, and biopterin (P = 0.040) was elevated, compared with control subjects. In sera from 35 persons with autism, among cytokines, only tumor necrosis factor receptor II was elevated compared with controls (P < 0.02). Decreased quinolinic acid and neopterin in cerebrospinal fluid are paradoxical and suggest dysmaturation of metabolic pathways and absence of concurrent infection, respectively, in autism. Alternatively, they may be produced by microglia but remain localized and not expressed in cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139734     DOI: 10.1016/j.pediatrneurol.2005.03.014

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  111 in total

1.  Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.

Authors:  Zuzana Tobiasova; Klaas H B van der Lingen; Lawrence Scahill; James F Leckman; Yan Zhang; Wookjin Chae; James T McCracken; Christopher J McDougle; Benedetto Vitiello; Elaine Tierney; Michael G Aman; L Eugene Arnold; Liliya Katsovich; Pieter J Hoekstra; Fred Volkmar; Alfred L M Bothwell; Ivana Kawikova
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-11-09       Impact factor: 2.576

2.  Microglia in the cerebral cortex in autism.

Authors:  Nicole A Tetreault; Atiya Y Hakeem; Sue Jiang; Brian A Williams; Elizabeth Allman; Barbara J Wold; John M Allman
Journal:  J Autism Dev Disord       Date:  2012-12

Review 3.  Improving the prediction of response to therapy in autism.

Authors:  Stephen Bent; Robert L Hendren
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.

Authors:  Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

Review 5.  Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.

Authors:  Evdokia Anagnostou; Robin Hansen
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

6.  Maternal exposure to intimate partner abuse before birth is associated with autism spectrum disorder in offspring.

Authors:  Andrea L Roberts; Kristen Lyall; Janet W Rich-Edwards; Alberto Ascherio; Marc G Weisskopf
Journal:  Autism       Date:  2015-02-06

7.  Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders.

Authors:  Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac N Pessah; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2010-11-20       Impact factor: 3.478

8.  Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.

Authors:  Arti B Patel; Irene Tsilioni; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

9.  Pathogenesis of autism: a patchwork of genetic causes.

Authors:  Elena L Grigorenko
Journal:  Future Neurol       Date:  2009

10.  Mental health comorbidity in patients with atopic dermatitis.

Authors:  Pouya Yaghmaie; Caroline W Koudelka; Eric L Simpson
Journal:  J Allergy Clin Immunol       Date:  2012-12-13       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.